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Background: To report an aggressive and treatment-resistant adenoid cystic carcinoma (ACC) of the lacrimal gland 
(LG). 
Case report: A 29-year-old woman with diagnosis of LG-ACC had operations 7 times, radiotherapy 3 times and 
systemic chemotherapy 2 times. Although she generally responded therapies, the duration of remissions was short lived 
and the tumor progressed locally and did hematogen metastases. 
Conclusion: LG-ACC presents a therapeutic challenge despite its slow growth rate and lower likelihood of lymph-node 
metastasis. Postoperative radiotherapy with wide margins should be utilized —even after a complete resection— 
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Introduction 
ACC encompasses %13.4 of LG tumors and consists of epithelial and myoepithelial cells with 
several morphological configurations [1, 2]. In spite of slow growth rate, persistent local 
recurrences and late distant metastases occur frequently. It often originates from parotid and 
submandibular glands and in rare instances, from the lacrimal gland  [2, 3]. Stage>T3, perineural 
invasion, a positive surgical margin, basaloid subtype, metastasis and recurrence are primary 
factors that adversely affect prognosis [4, 5]. The disease-specific and overall survival rates at 
10-year follow-up were given as %51.4 and %38.7 respectively [1].
 
Metastasis can occur one-third 
of patients, with lung, liver, brain and bone being the most common metastasis sites  [4]. The 
primary therapeutic approach for ACC is surgery of the lacrimal gland; however, aggressive 
surgery and enucleation do not improve survival [4, 5]. The addition of adjuvant radiotherapy to 
surgery significantly improves local control rates [2-4]. Chemotherapy is generally used in 
recurrent or inoperable cases [2]. 
Here, we discuss the role, effectiveness and relevance of multi-modality therapy in a patient 
with metachronous ACC, which developed in bilateral lacrimal glands in three years intervals.  
 
 
Figure 1 Adenoid cystic carcinoma of LG. Tumoral infiltration of solid, cribriform and tubular pattern 
are observed (H & E, X100) 
Case summary 
A 29-year-old woman who had a normal delivery 2 months ago presented to a University 
Ophthalmology Clinic with an anterior and medial protrusion of the left eye. She was diagnosed 
with biphasic (epithelial and myoepithelial) tumor by a fine-needle aspiration biopsy (FNAB) 
performed in March 2009. On magnetic resonance imaging (MRI) of the orbit, a mass lesion 
(4x3x3.2 cm) with non-homogenous contrast enhancement was detected at the left lacrimal gland, 
which invaded the lateral wall of the left orbit and had intermediate signal intensity on T1-weighted 
images and a hyper-intense signal on T2-weighted images. Chest and whole abdominal computed 
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tomography scanning with contrast showed no systemic metastases. In May 2009, the patient 
underwent mass excision and bone curettage in another University Hospital. Histopathological 
evaluation revealed basaloid subtype of ACC with invasion of frontal bone (Figure 1).  
Immunohistochemical studies with keratin and smooth muscle actin (SMA) shoved intrastoplasmic 
positivity. On the restaging MRI following surgery, a residue (4x3x1 cm) was seen in the left 
retro-orbital adipose tissue at the vicinity of the lateral rectus muscle; as a result, re-excision was 
performed in June 2009. Again, a strip-like residual tissue (3x3x0.3 cm) was observed on the 
follow-up MRI after re-excision. Then, fractionated stereotactic radiotherapy (FSRT) was given to 
the left lacrimal gland and frontal region by using CyberKnife Robotic Radiosurgery system 
(Accuray, Sunnyvale, California) in June 2009. FSRT was delivered with 24 Gy in 3 fractions 
to %72 isodose (Figure 2). No complication other than Grade I conjunctivitis was observed during 
therapy. On the follow-up MRI and computed tomography (CT) scan after FSRT, we observed a 





















On the follow-up MRI in March 2010, recurrence (1.8x1.2x1.0 cm) was evident in the 
zygomatic bone corresponding to the inferior region of the left orbit. In addition, metastases were 
evident in the left frontal bone (2.0x1.2 cm), in the inner tabula adjacent to the sylvian fissure   
(7x7 mm) and in the middle left region of the cranial fossa (1.3x1.2 cm) (Figure 4). Metastasis a t 
the frontal bone was excised in April 2010. Histopathological evaluation was reported as frontal 
bone invasion by ACC. The patient received 6 sessions of a chemotherapy regimen in 28 -day 
intervals, consisting of cyclophosphamide (500 mg/m
2
), doxorubicin (50 mg/m
2
) and cisplatin   
(50 mg/m
2
). The postoperative clinicopathological evaluation was considered to be stable disease. 
Unfortunately, disease progression in the middle left region of the cranial fossa and inner tabula 
adjacent to the sylvian fissure was detected in a follow-up visit in November 2010. Tumor excision 
via a left petrous craniotomy in the frontal lobe was performed for the fourth time, and the defect 
was repaired using titanium plates. Histopathological evaluation was reported as ACC. Between 
Figure 2 CyberKnife plan. 
Figure 3 The CT scan with contrast 
enhancement shows that the masses in the 
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December 2010 and January 2011, image-guided intensity-modulated radiotherapy (IG-IMRT) via 
Tomotherapy using 2 Gy daily fractions up to 60 Gy at 2 phases was delivered to all metastatic 
lesions and osseous involvement sites (Figure 5). Dose was limited to 50 Gy in areas that 
previously received radiotherapy by stereotactic surgery. No complication other than Grade II 
conjunctivitis was observed. The follow-up MRI after radiotherapy detected that lesions at the 
middle cranial fossa and the sylvian fissure, which were observed on previous imaging studies, 

















Figure 5 Sagittal, coronal and axial images of Tomotherapy planning shows the first Tomotherapy 
irradiation volumes of metastatic areas. 
Figure 4 T1 weighted MRI with contrast shows that there is 
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Figure 6 T1 weighted MRI with contrast shows that there were rapid progression of lesions in 
ethmoid sinus area and new formation of tumoral mass at lateral wall of the right orbit that leads 
expansion towards to the right temporal region 
 
On follow-up MRI in September 2011, marked progression was observed in the mass lesion at 
the inferolateral wall of the left orbit and right half of the frontal sinus. The tumor was excised 
from the frontal region via partial maxillectomy in October 2011. Histopathologica l evaluation was 
reported as persistent ACC at soft tissues and osseous tissue. After surgery, the patient received 6 
sessions of paclitaxel (75 mg/m
2
). Under the paclitaxel chemotherapy, there were rapid progression 
of lesions in ethmoid sinus area and new formation of tumoral mass at lateral wall of the right orbit 
that leads expansion towards to the right temporal region. This new mass lesion originating from 
the contralateral lacrimal gland was excised. Histopathological evaluation was reported as ACC. 
Because of clinical and radiological progression and the onset of severe pain, IG-IMRT was 
delivered with 46 Gy in 2 Gy fractions (5 fractions per week) to all metastatic lesions and osseous 
involvement sites using tomotherapy between May and June 2012. IG-IMRT provided sufficient 
pain control, but the patient died in December 2012 due to disease progression.  
Discussion 
An epidemiologic study from the ‘Surveillance Epidemiology and End Results database’ by 
Andreoli et al, shows that lymphoma (%58), ACC (%13.4), adenocarcinoma (%3.8) and 
mucoepidermoid carcinoma (%3.6) accounted for most LG tumors [1]. ACC is usually seen in 
women ages 35-45 and involves the left LG more frequently [1-3]. In a study by Weis et al., ACC 
was reported in %29 to %64 of all malignant lacrimal gland tumors [8]. In a study by Chawla et al. 
involving 66 cases, the most common malignant type was ACC with a frequency of %75; a median 
age of 32 years and the left side as the most common area of localization [3]. The majority of 
patients present with complaints of proptosis, ptosis, pain and diplopia. At diagnosis, there is a 
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palpable mass at the lateral margin of orbit in %50 of patients, preoperative pain in %9 and bone 
erosion in %50 [1-3].
 
CT and MRI are helpful in identifying osseous invasion and tumor spread to 
adjacent organs. In our case, the patient presented to us with proptosis. She also experienced severe 
pain as the disease progressed and as a second primary LG developed. CT and MRI were used in 
diagnosis and follow-up.   
Complex anatomy of the orbit and aggressive bone invasion are the main difficulties when 
considering surgery of LG tumors. Because bone invasion occurs at an early phase in cancers of the 
region, surgery is supported by radiotherapy in most cases [3-8]. Tissue-sparing surgical techniques 
with low morbidity and reconstructive approaches followed by loco-regional conformal 
radiotherapy should be considered as an optimal therapeutic option. Some radiation oncologists 
recommend radiotherapy to all patients, including those who underwent complete resection. Others 
recommend radiotherapy in the presence of poor prognostic factors, including a T3 tumor, 
advanced stage, perineural invasion, basaloid subtype and a positive surgical margin. However, 
despite adjuvant radiotherapy, outcomes are still not promising [4, 7, 8]. 
Ongoing debate continues regarding tumor volumes and margins that can be treated by 
radiotherapy. In recent years, novel technological advances such as IMRT, IG-IMRT, neutron and 
proton therapies have reduced radiotherapy volumes and decreased radiation exposure to healthy 
tissue [9-12]. As Douglas et al. report, these sophisticated modalities are superior to conventional 
methods in treating LG tumors [6].
 
However, clinical experience is scarce in such modalities. Our 
patient underwent surgery 7 times, radiotherapy 3 times and systemic chemotherapy twice. 
Radiotherapy was given in case of a partial resection, recurrence and /or metastasis. This resulted in 
a complete response in dural and parenchymal metastases of brain, but only provided stable disease 
in bone metastasis. In addition the patient experienced an 8-month recurrence-free period after 
palliative radiotherapy. 
Generally, chemotherapy is given to patients with recurrent or inoperable disease. Currently, 
chemotherapy is used as an adjuvant therapy to improve response and survival rates achieved by 
other therapeutic modalities. However, reports indicate that single- or multi-drug chemotherapy 
regimens are associated with low response rates and shorter remission periods [2, 9].
 
In our case, 
first systemic chemotherapy resulted instable disease. Despite shorter remission periods, it was 
thought that systemic chemotherapy was effective in disease control. However,  disease progression 
was evident, as there was no response from the second chemotherapy treatment (paclitaxel).  
In %80 of reported cases, recurrence surfaces within 5 years [4]. Factors influencing prognosis 
include age, gender, tumor localization, recurrence time, histological type, perineural and vascular 
invasion and positive surgical margin [1, 2, 5, 10]. In our case, disease progression persisted 
despite multi-modal therapy and the patient died 46 months after diagnosis. 
Conclusion 
Lacrimal gland ACC presents a therapeutic challenge despite its slow growth rate and lower 
likelihood of lymph-node metastasis. Postoperative radiotherapy with wide margins should be 
utilized—even after a complete resection—because of persistent recurrences, perineural invasion 
and hematogenous spread. 
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